Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review
Lanadelumab dosing intervals can be individualized to maintain effective disease control. A dosing interval extension may be considered in well-controlled disease.
Authors
- Louise Yu (ORCID: https://orcid.org/0000-0002-9401-0351)
- Maureen Watt (ORCID: https://orcid.org/0000-0002-7868-2625)
- Louise Clear (ORCID: https://orcid.org/0009-0008-0038-9497)
- Maral DerSarkissian (ORCID: https://orcid.org/0000-0002-5528-6531)
- Rose Chang
Institutions
- Takeda (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1007/s40801-025-00505-x
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 1.63